News
Genentech announced that the Food and Drug Administration (FDA) has approved Tecentriq (atezolizumab) for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) who have disease progression during or following platinum-containing chemotherapy, and have progressed on an appropriate FDA-approved targeted therapy if their tumor has EGFR or ALK gene abnormalities.
Drugs in the Pipeline
GTx announced the continuation clinical development as planned with its two pivotal Phase 3 trials of enobosarm (GTx-024) for the prevention and treatment of muscle wasting in patients with non-small cell lung cancer.
Drugs in the Pipeline
The sBLA is supported by data from the phase 2 DESTINY-Lung01 trial, along with a phase 1 trial published in Cancer Discovery.
Drug News
Postoperative radiation therapy (PORT) is not associated with improved survival for elderly patients with N2 non-small-cell lung cancer (NSCLC).
Drugs in the Pipeline
Synta announced results from its Phase 2 study of ganetespib (STA-9090) for the treatment of NSCLC.
Drug News
Molecular differences have been identified in small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC) cell lines, which may represent potential therapeutic targets.
Drugs in the Pipeline
AbbVie announced that the Food and Drug Administration (FDA) has granted Orphan Drug Designation to veliparib, an investigational combination with chemotherapies or radiation for the treatment of advanced squamous non-small cell lung cancer (NSCLC).
Drug News
For Medicare beneficiaries with non-small-cell lung cancer, demographic differences in the rates of positron emission tomography scan use persisted from 1998 to 2007.
Drug News
For some, but not all, nonmelanoma cancers, BRAF V600 is a targetable oncogene, with activity seen in non-small-cell lung cancer and Erdheim-Chester disease and Langerhans'-cell histiocytosis.
Trial Tracker
Peters, S et al. "Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer." DOI: 10.1056/NEJMoa1704795
